期刊文献+

沙利度胺对双膦酸盐相关颌骨坏死的影响 被引量:3

Effect of thalidomide on development of bisphosphonate- related osteonecrosis of the jaws in rats
在线阅读 下载PDF
导出
摘要 目的研究沙利度胺对双膦酸盐相关颌骨坏死的影响。方法 36只大鼠随机分成A、B、C组,分别接受生理盐水、唑来膦酸、唑来膦酸+沙利度胺治疗。用药3周后,拔除大鼠左上颌第1磨牙。拔牙后4、8周,收获标本,评价颌骨坏死、微血管生成及细胞凋亡情况。结果拔牙后4、8周,大鼠上颌骨拔牙创处均无死骨裸露,但B组、C组部分标本可见一些小的瘘管。组织学检查显示,A组标本未见死骨,而B组、C组在拔牙窝周围可见小块死骨。B组、C组拔牙窝周围区域空骨陷窝百分比和死骨面积显著多于A组(P<0.01),而骨陷窝密度则显著下降。B组、C组微血管密度较A组也显著降低,在4周时分别下降了和25.87%和55.27%(P<0.01),在8周时分别下降了45.62%和72.84%(P<0.01);凋亡细胞数则在4周时分别增长了54.80%和87.89%(P<0.01),在8周分别增长了208.08%和250.58%(P<0.01)。结论沙利度胺加重了唑来膦酸诱发的早期阶段的颌骨坏死;沙利度胺和唑来膦酸对颌骨坏死的作用与微血管生成抑制有关。 Objective To investigate the effect of thalidomide on the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ). Methods Thirty-six rats were randomly divided into groups A, B and C, and treated with saline, zoledronate and zoledronate plus thalidomide, respectively. Three weeks later, the left maxillary first molars of the rats were extracted. Four and eight weeks after tooth extraction, samples were harvested for evaluation of osteonecrosis of the jaws, microvessel density, and cell apoptosis. Results At both of the time points, no exposed dead bone was observed at the extraction socket areas in the rats except for some small fistulas in groups B and C. Histological examination confirmed the absence of dead bone in group A, whereas small areas of dead bone were observed around the extraction socket in groups B and C. Compared with those in group A, the percentage of empty lacunae and the area of dead bone were significantly increased (P〈0.01), whereas bone lacunae density was significantly decreased (P〈O.01) in groups B and C at both time points. Microvessel density in groups B and C were also significantly decreased (P〈0.01) by 25.87% and 55.27% at week 4, and by 45.62% and 72.84% at week 8, respectively; the apoptotic cells in groups B and C increased by 54.80% and 87.89% at week 4 (P〈0.01), and by 208.08% and 250.58% at week 8 (P〈0.01), respectively. Conclusion Thalidomide can aggravate zoledronate-induced early-stage BRONJ, and their osteonecrosis-inducing effect of the jaw may be attributed, at least partly to the inhibition of angiogenesis.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2015年第8期1084-1089,共6页 Journal of Southern Medical University
基金 国家自然科学基金(81270965 81101448) 河北省自然科学基金(C2011401044)~~
关键词 唑来膦酸 血管生成 双膦酸盐 颌骨坏死 沙利度胺 zoledronate angiogenesis bisphosphonate osteonecrosis, jaw thalidomide
  • 相关文献

参考文献23

  • 1黄如冰,吴晓林,俞娟.双磷酸盐相关性颌骨坏死12例临床分析[J].中华口腔医学研究杂志(电子版),2012,6(4):31-34. 被引量:16
  • 2彭诚,王东.双膦酸盐类药物治疗相关的下颌骨坏死的研究进展[J].医学综述,2011,17(8):1181-1183. 被引量:3
  • 3Ruggiero SL,Dodson TB,Assael LA,et al.American association of oral and maxillofacial surgeons position paper on bisphosphonate- related osteonecrosis of the jaws-2009 update[J I.J Oral Maxillofac Surg,2009,67(5 Suppl):2-12.
  • 4Christodoulou C,Pervena A,Klouvas G,et al.Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone [J].Oncology,2009,76(3):209-11?.
  • 5Bi Y,Gao Y,Ehirchiou D,et al.Bisphosphonates cause osteonecrosis of the jaw-like disease in mice [J].Am J Pathol,2010,177(1):280-90.
  • 6Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors [J].Breast Cancer Res Treat,1995,36(2):169-80.
  • 7Bolomsky A,Schreder M,MeiBner T,et al.Immunomodulatory drugs Thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro [J].Exp Hematol,2014,42(7):516-25.
  • 8Cankaya AB,Erdem MA,Isler SC,et al.Use of cone-beam computerized tomography for evaluation of bisphosphonate- associated osteonecrosis of the Jaws in an experimental rat model [J].Int J Med Sci,2011,8(8):667-72.
  • 9Pautke C,Kreutzer K,Weitz J,et al.Bisphosphonate related osteonecrosis of the jaw:a minipig large animal model [J].Bone,2012,51(3):592-9.
  • 10Kumar S.Anderson KC.Drug insight:thalidomide as a treatment for multiple myeloma[J].Nat Clin Pract Oncol,2005,2(5):262-70.

二级参考文献30

  • 1Pogrel MA.Bisphosphonates and bone necrosis[J].J Oral Maxillofac Surg,2004,62(3):391-392.
  • 2Wang J,Goodger NM,Pogrel MA.Osteonecrosis of the jaws associated with cancer chemotherapy[J].J Oral Maxillofac Surg,2003,61(9):1104-1107.
  • 3Marx RE,Sawatari Y,Fortin M,et al.Bisphosphonate induced exposed bone(osteonecrosis/osteopetrosis)of the jaw[J].J Oral Maxillofac Surg,2005,63(11):1567-1575.
  • 4Shinoda H,Takeyama S,Suzuki K,et al.Pharmacological topics of bone metabolism:a novel bisphosphonate for the treatment of periodontitis[J].J Pharmacol Sci,2008,106(4):555-558.
  • 5Woo SB,Hellstein JW,Kalmar JR.Narrative[corrected] review:bisphosphonates and osteonecrosis of the jaws[J].Ann Int Med,2006,144(10):753-761.
  • 6Sarathy AP,Bourgeois SL Jr,Goodell GG.Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment:two case reports[J].J Endod,2005,31(10):759-763.
  • 7Reuther T,Schuster T,Mende U,et al.Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients--a report of a thirty year retrospective review[J].Int J Oral Maxillofac Surg,2003,32(3):289-295.
  • 8Ibrahim T,Barbanti F,Giorgio-Marrano G,et al.Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates:a retrospective study[J].Oncologist,2008,13(3):330-336.
  • 9Pongchaiyakul C,Auraiwan K,Kotruchin P,et al.Bisphosphonate-related osteonecrosis of the jaws (ONJ):a report of two cases[J].J Med Assoc Thai,2007,90(11):2494-2498.
  • 10Kicken M,Van Cann EM,Koole R.Bisphosphonate-associated osteonecrosis of the jaws.2.Six case reports[J].Ned Tijdschr Tandheelkd,2007,114(10):428-431.

共引文献17

同被引文献35

  • 1房桂珍,李为民,刘东刚.双膦酸盐类药物引起的下颌骨坏死[J].中国肿瘤临床,2007,34(18):1069-1071. 被引量:10
  • 2Smith MR, Saad F, Coleman R, et al. Denosumab and bone- metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 2012, 379(9810): 39-46.
  • 3Ruggiero SL, Dodson TB, Famasia 5, et aL American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg, 2014,72(10): 1938-1956.
  • 4Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ, 2003, 327(7413): 469.
  • 5Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer, 2008, 113(6): 1438-1445.
  • 6Fusco V, Bedogni A, Campisi G. Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab. Support Care Cancer, 2014, 22 (7): 1737-1738.
  • 7Beuselinck B, Woher P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer, 2012, 107(10): 1665-1671.
  • 8Fusco V, Porta C, Saia G, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an italian muhicenter study and review of the literature. Clin Genitourin Cancer, 2015, 13(4): 287-294.
  • 9Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase m trials in cancer patients with bone metastases. Ann Oncol, 2012, 23 (5): 1341-1347.
  • 10Van den Wyngaert T, Wouters K, Huizing MT, et ah RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer, 2011, 19( 12): 2035-2040.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部